KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Cash (2020 - 2025)

Recursion Pharmaceuticals' Change in Cash history spans 6 years, with the latest figure at $86.8 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 48.1% year-over-year to $86.8 million; the TTM value through Dec 2025 reached $150.9 million, down 25.15%, while the annual FY2025 figure was $150.9 million, 25.15% down from the prior year.
  • Change in Cash reached $86.8 million in Q4 2025 per RXRX's latest filing, down from $133.3 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $423.8 million in Q2 2021 to a low of -$238.0 million in Q3 2021.
  • Average Change in Cash over 5 years is $24.3 million, with a median of -$9.4 million recorded in 2022.
  • Peak YoY movement for Change in Cash: tumbled 2615.0% in 2023, then skyrocketed 3863.8% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$109.6 million in 2021, then surged by 185.97% to $94.2 million in 2022, then crashed by 95.52% to $4.2 million in 2023, then surged by 3863.8% to $167.2 million in 2024, then plummeted by 48.1% to $86.8 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Change in Cash are $86.8 million (Q4 2025), $133.3 million (Q3 2025), and $24.7 million (Q2 2025).